Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

BRCAness refers to tumors that mimic BRCA1/2 mutation behavior, making them vulnerable to DNA-damaging treatments like PARP ...

There were 22 men with progressive mCRPC enrolled, the median age at enrollment was 66 years (range 52-80), the median PSA at original diagnosis was 82 ng/mL (range 5-3,648), 55% had a Gleason score 9 ...

Oncology specialists from UC San Francisco will present new clinical research findings and cutting-edge treatment strategies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Genetic testing for hereditary cancer unexpectedly uncovers a case of myelodysplastic syndrome (MDS), highlighting the need ...

Former EastEnders star has revealed that she has undergone a double mastectomy, following a gene test which confirmed she ...

Doctors examine a tumor in several different ways to determine whether a cancer is aggressive – and what kinds of treatments, ...

Data to be presented at ASCO reflect Boehringer's broad pipeline and growing body of evidence supporting innovative therapies for various cancersPatient-reported outcomes from the Beamion LUNG-1 study ...

This can be performed on the tumor tissue itself to identify changes called somatic mutations that ... more commonly ...

discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Initially, ESR1 mutations are rare in newly diagnosed patients, ...